Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07530770 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 21, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Secondary endpoints: details revised at 2 of 3 entriesv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
Trial Details
NCT Number NCT07530770
Lead Sponsor Qianfoshan Hospital
Conditions
(from sponsor)		 Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
Related terms Aspergillosis, Allergic Bronchopulmonary, Asthma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov